Dr Pierre Saintigny speaks to ecancer at the WIN 2019 Symposium in Paris about a new initiative that uses the exchange of clinical and genetic data from patients that have been included in precision medicine or molecular triage clinical trials.

He explains the idea and structure behind this program, which aims to learn more about some of the more obscure genomic alterations and to determine their association with certain drugs.

Dr Saintigny also describes how data quality is ensured, which incorporates both clinical and genomic items into models that take the long-term evolution of the patient into account.

For the future, this initiative will include more retrospective patients and to utilise this data in a prospective manner.

Dr Saintigny also discusses the possibility of expanding the initiative on a global scale.